LifeArc

Tribune Therapeutics is a preclinical biopharmaceutical company focused on developing medicines to treat fibrotic diseases by targeting extracellular matrix–associated proteins central to scar formation, with the aim of halting progression across diverse tissues and conditions.

Hillstar Bio is a biopharmaceutical company focused on developing precision immunotherapies for treating autoimmune diseases. Its innovative approach selectively targets and depletes harmful immune cells, sparing healthy ones, to address specific disease mechanisms and reduce the risks associated with chronic broad immunosuppression. The company aims to provide durable relief and immune reset for patients with autoimmune conditions, addressing unmet medical needs.

Maxion Therapeutics develops a novel platform to generate antibody-like therapeutics targeting ion channels and GPCR-driven diseases. The platform incorporates venom-derived knottins into antibody surfaces to create mixtures with optimized drug-like properties, enabling treatments for conditions such as chronic pain, autoimmune disorders, and heart disease. The company aims to deliver long-acting, safe, and effective medications against previously inaccessible targets.

Fluid Biomed is a medical device start-up specializing in the development of an innovative implantable dissolving stent aimed at treating brain aneurysms. Founded by a team of neurosurgeons, the company focuses on enhancing patient outcomes by offering a bio-absorbable polymer-based flow-diverting stent that gently redirects blood flow to facilitate the healing of weakened blood vessels. This advanced medical device is designed to minimize the need for invasive procedures, allowing physicians to efficiently and effectively treat patients while reducing the risk of stroke. Through its pioneering approach, Fluid Biomed is poised to contribute significantly to the field of neurosurgery and improve the quality of care for individuals with brain aneurysms.

Ikarovec is a gene therapy company focused on developing early-stage treatments for common eye diseases, particularly diabetic macular edema. The company aims to address multiple disease targets and pathways, working on therapies that also target dry-form age-related macular degeneration, neovascular (wet-form) age-related macular degeneration, and ocular hypertension. By advancing these innovative treatments, Ikarovec seeks to provide effective solutions for patients, helping to restore sight and prevent blindness.

Ozlo Sleep is a science-driven sleep and audio technology company that supports and simplifies sleep rituals for clinical benefits, without the use of medication.

Ozlo Sleep is a science-driven sleep and audio technology company that supports and simplifies sleep rituals for clinical benefits, without the use of medication.

Affect Therapeutics offers an integrated digital treatment program for drug and alcohol addiction via a mobile app. The program uses contingency management and other reward systems to encourage healthy behaviors and new habits, aiming to improve member retention and better outcomes.

Maxion Therapeutics develops a novel platform to generate antibody-like therapeutics targeting ion channels and GPCR-driven diseases. The platform incorporates venom-derived knottins into antibody surfaces to create mixtures with optimized drug-like properties, enabling treatments for conditions such as chronic pain, autoimmune disorders, and heart disease. The company aims to deliver long-acting, safe, and effective medications against previously inaccessible targets.

OXcan is a startup that focuses on early detection of lung cancer using advanced machine learning and liquid biopsy technologies. The company has developed an artificial intelligence-based healthcare platform that identifies cancer by analyzing targeted blood tests. This platform detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine screening. By evaluating multidimensional liquid biopsy results, which include DNA, proteins, epigenetic markers, and patient medical histories, OXcan enables healthcare providers to achieve early cancer detection and implement curative treatment strategies.

Cytospire Therapeutics specializes in developing a portfolio of innovative, next-generation immune cell engagers. These are multispecific antibodies designed to enhance and direct the power of key effector cells in the immune system, offering patients more effective treatments compared to existing therapies.

Surgery Hero is a pioneering digital prehabilitation clinic that focuses on preparing individuals for surgery and facilitating their recovery in the comfort of their homes. The company offers a digital care platform designed for surgery preparation, perioperative care, and post-operative recovery. By utilizing expert health coaches and providing digital guidance, Surgery Hero helps clients adopt lifestyle habits that are scientifically proven to enhance surgical outcomes. This approach not only optimizes both physical and mental readiness prior to surgery but also aims to reduce the risk of complications and accelerate the recovery process.

AviadoBio focuses on developing transformative gene therapies for devastating neurodegenerative disorders such as frontotemporal dementia and amyotrophic lateral sclerosis. The company's platform combines proprietary technologies with a deep understanding of the brain to deliver effective treatments.

Closed Loop Medicine designs and develops healthcare technology software that optimizes drug dosing on an individual level through integrated digital therapies. The company focuses on improving patient outcomes for chronic diseases, with products in development for hypertension and insomnia.

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, that specializes in developing therapeutic drugs for hyperexcitability disorders affecting the nervous system. Founded in 2018, the company focuses on creating innovative treatments for conditions such as chronic pain, depression, epilepsy, and anxiety, which significantly impact millions of individuals. Eliem utilizes its expertise in neuroscience and translational medicine to advance a promising pipeline of drug candidates, including its lead candidate, ETX-155, aimed at addressing major depressive disorder and focal onset seizures. The company's mission centers on meeting unmet medical needs and improving patients' quality of life through its novel therapies.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

DJS Antibodies Ltd is a biotechnology company based in Bicester, United Kingdom, established in 2014. The company focuses on the design and discovery of novel therapeutic monoclonal antibodies specifically targeting G-protein-coupled receptors (GPCRs). DJS Antibodies aims to develop innovative therapeutics for chronic inflammatory diseases by utilizing its advanced technology to create first-in-class antibody therapeutics for previously challenging disease targets. By specializing in the research and discovery of functional antibodies against complex protein targets that have eluded traditional drug discovery efforts, DJS Antibodies endeavors to provide effective treatments for diseases that are currently considered undruggable and untreatable.

BrainWaveBank, established in 2015, is a UK-based brain health research company. It specializes in developing data-centric solutions to track and understand cognitive health. The company's flagship product, also named BrainWaveBank, is a wearable EEG headset that measures brain activity while users engage in mobile games, enabling daily tracking of cognitive health at home. This data is securely stored and analyzed, creating neurocognitive profiles for individuals and populations, and aiding clinical professionals in advancing brain health research and treatments. The company has offices in Belfast, Northern Ireland, and Dublin, Ireland.

Brightlobe is a London-based developer of game-based tools for healthcare that support children's growth and development. Founded in 2012, Brightlobe creates tablet games and an integrated platform designed to be used by healthcare providers to monitor development and deliver early interventions. Its flagship early detection system targets pediatric autism and ADHD and is in Phase 2 clinical trials in the United States and the United Kingdom. The solution integrates with popular game engines, enables real-time participant tracking, and relies on evidence-based methodologies drawn from game design, machine learning, and cognitive neuroscience. By combining engaging gameplay with clinically relevant assessments, Brightlobe aims to improve early identification and intervention for children with developmental concerns and conditions, supporting clinicians in delivering timely care and better outcomes.

Vicore Pharma is a clinical-stage pharmaceutical company focused on severe lung diseases. It develops medicines that act through the angiotensin II type 2 receptor, with its lead candidate C21 currently in phase 2b development for idiopathic pulmonary fibrosis and holding orphan drug designation in the European Union and the United States. The company is exploring additional rare diseases in which the AT2 receptor plays a key role. It is based in Mölndal, Sweden, in AstraZeneca’s Bioventurehub, and, in addition to its drug program, is pursuing a digital therapeutic approach with Almee, an investigational medical device designed to address the psychological impact of living with pulmonary fibrosis.

PolyProx Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, founded in 2018. It focuses on researching and developing innovative drug therapies aimed at treating cancer and neurodegenerative diseases. The company's flagship product, Polyproxin, utilizes engineered proteins that selectively target tumor cells. This mechanism activates the natural degradation processes within the cells, allowing for the removal of disease-causing proteins. By employing this novel approach, PolyProx aims to provide effective treatment options for cancer patients, potentially improving their outcomes and quality of life.

Ikarovec is a gene therapy company focused on developing early-stage treatments for common eye diseases, particularly diabetic macular edema. The company aims to address multiple disease targets and pathways, working on therapies that also target dry-form age-related macular degeneration, neovascular (wet-form) age-related macular degeneration, and ocular hypertension. By advancing these innovative treatments, Ikarovec seeks to provide effective solutions for patients, helping to restore sight and prevent blindness.

AviadoBio focuses on developing transformative gene therapies for devastating neurodegenerative disorders such as frontotemporal dementia and amyotrophic lateral sclerosis. The company's platform combines proprietary technologies with a deep understanding of the brain to deliver effective treatments.

Caldan Therapeutics Ltd is a biotechnology company formed as a spinout from the University of Glasgow and the University of Southern Denmark. The company is focused on developing innovative therapeutics that target free fatty acid receptors, which play a significant role in the pathophysiology of metabolic diseases such as Type 2 Diabetes (T2D). The collaboration between Professors Graeme Milligan and Trond Ulven has led to the identification of these receptors as promising targets for addressing various aspects of T2D, including insulin secretion, sensitivity, and cellular protection. In addition to T2D, Caldan Therapeutics is exploring the potential of its technology to treat other conditions, including non-alcoholic steatohepatitis (NASH) and inflammatory diseases.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to develop medicines for severe rare diseases and cancer. It maintains a differentiated targeted oncology portfolio with lead candidates nirogacestat, a gamma secretase inhibitor, and mirdametinib, a MEK inhibitor, both in late-stage trials; the pipeline also includes BGB-3245, an oral inhibitor of activating BRAF mutations, in Phase I, and several combination programs. The company pursues collaborations with BeiGene, GlaxoSmithKline, and Allogene and has license agreements with Pfizer for nirogacestat and mirdametinib. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks aims to advance potentially registrational studies in rare tumor types and genetically defined cancers through partnerships that expand its portfolio and patient access.

AMR Centre Limited, established in 2016 and headquartered in Macclesfield, UK, specializes in the development of novel antibiotics to combat antimicrobial resistance. The company offers its expertise and facilities to global pharmaceutical entities on a collaborative basis, with an agreement to share commercially in any successful new products resulting from these partnerships.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to develop medicines for severe rare diseases and cancer. It maintains a differentiated targeted oncology portfolio with lead candidates nirogacestat, a gamma secretase inhibitor, and mirdametinib, a MEK inhibitor, both in late-stage trials; the pipeline also includes BGB-3245, an oral inhibitor of activating BRAF mutations, in Phase I, and several combination programs. The company pursues collaborations with BeiGene, GlaxoSmithKline, and Allogene and has license agreements with Pfizer for nirogacestat and mirdametinib. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks aims to advance potentially registrational studies in rare tumor types and genetically defined cancers through partnerships that expand its portfolio and patient access.

GlycoEra is a biotechnology research company focused on developing innovative therapeutics that target significant unmet medical needs in inflammatory and autoimmune diseases, as well as in immune-oncology. The company has established a proprietary platform that enables the creation of first-in-class biologics by assembling customized and highly homogeneous human glycans onto glycoproteins in a site-specific manner. This approach facilitates a deeper understanding of the role of glycans in human health and disease, positioning GlycoEra to contribute meaningfully to the advancement of novel treatment options in the healthcare sector.